Aproxol Plus

Quick links to important sections

Aproxol Plus

Treatment option: Pain

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aproxol Plus

Property Description
Active ingredients Acetaminophen, Tramadol Hydrochloride
Form Oral tablet
Pharmacological class Narcotic analgesic combination, Centrally-acting opioid analgesic
General purpose Symptomatic treatment of pain
Origin Synthetic

Aproxol Plus is defined as a fixed combination medicinal product, formulated as an oral tablet for systemic relief, fundamentally combining two distinct analgesic compounds to modify the perception of pain. The two active ingredients are the non-opioid Acetaminophen (Paracetamol) and the synthetic opioid analgesic, Tramadol Hydrochloride. This strategic combination is classified as a Narcotic analgesic combination, a designation clinically recognized for addressing pain that has not responded adequately to alternative, single-agent treatments.

Composition and Classification: What Type of Medicine is Aproxol Plus?

The product is categorized as a combination drug because it delivers two separate analgesic agents in a single oral tablet. This design utilizes the distinct, yet complementary, analgesic effects of Acetaminophen and Tramadol Hydrochloride. The presence of Tramadol Hydrochloride confirms its identity as a centrally-acting opioid analgesic, which is a prescription-only (Rx) medicine due to its action on the μ-opioid receptors and its potential for dependence. Other common brand names utilizing this specific fixed combination formulation include Ultracet, ensuring that the pharmacological class remains consistent across different commercial presentations.

The Analgesic Strategy: How Does This Combination Work for Pain Relief?

The core general purpose of Aproxol Plus is the enhanced symptomatic treatment of pain by engaging multiple pain-modulating pathways simultaneously. This strategy is achieved through the complementary physiological actions of its ingredients: Acetaminophen contributes to pain relief via central mechanisms that help to increase the pain threshold, while Tramadol acts to modify pain messaging through both μ-opioid receptor binding and the inhibition of neurotransmitter reuptake. This layered approach provides broader pain relief than either active ingredient could offer independently, making it a critical tool in comprehensive pain pharmacotherapy.

What side effects are possible with Aproxol Plus?

Possible Side Effects and Safety Information

The official safety profile for Aproxol Plus (Acetaminophen/Tramadol Hydrochloride) is structured around documented adverse reactions, serious warnings, and high-level usage restrictions, as determined by regulatory authorities.


Frequency-Classified Adverse Reactions

The incidence of possible adverse effects is classified according to regulatory standards:

  • Very Common (ge 1/10): Nausea, Dizziness, and Somnolence (Drowsiness).
  • Common (ge 1/100 to < 1/10): Vomiting, Constipation, Dry Mouth, Headache, Sweating, Anxiety, Insomnia, Tremor, and Anorexia.

These effects are typically classified under Gastrointestinal Disorders and Nervous System Disorders in official labeling.


Serious Adverse Reaction Warnings

Official regulatory documents highlight several major risks requiring attention:

  • Respiratory Depression: A serious, potentially fatal risk associated with the opioid component, which is monitored closely during treatment initiation.
  • Hepatotoxicity: The risk of severe liver injury is associated with the Acetaminophen component, particularly in cases of overdose or pre-existing liver impairment.
  • Seizures and Serotonin Syndrome are also documented as potential serious adverse reactions.

Population-Specific Constraints and Safety Patterns

The product is contraindicated in children under 12 years of age and in individuals with severe hepatic impairment. Due to the risk of Neonatal Opioid Withdrawal Syndrome, prolonged use during pregnancy is a documented safety concern. Furthermore, adverse reactions like Nausea and Dizziness are often reported as more frequently observed at the beginning of treatment, and the potential for physical dependence and tolerance is a known risk associated with long-term use.

Overdose and Emergency Response

Overdose and when to seek help: Aproxol Plus

Official Overdose Information

Overdose with this medication, containing paracetamol (acetaminophen), is a dose-dependent hepatic injury capable of causing severe toxicity. Initial symptoms commonly include nausea and vomiting, which may progress to hepatic necrosis (severe liver damage) and acute liver failure, and in some cases, renal failure.

Overdose risk is elevated with the ingestion of large amounts over a short period. Patients with alcohol use or poor nutritional status may have an increased risk of hepatotoxicity. Additionally, overdose involving modified-release formulations is considered particularly high-risk due to sustained drug absorption.

Immediate medical help is required for any suspected overdose. Emergency procedures detailed in regulatory documents emphasize the prompt administration of N-acetylcysteine as the antidote, ideally within the first eight hours following ingestion to minimize the risk of developing fulminant liver failure. Treatment decisions are guided by monitoring serum acetaminophen concentration relative to the time of ingestion.

Overdose Classification Details from Regulatory Documents
Severity Classification Leads to Severe Acute Liver Injury and Death
Response Requirement Immediate medical attention for suspected ingestion

Therapeutic Uses of Aproxol Plus

What Aproxol Plus Treats: Main Uses and Benefits

Aproxol Plus is commonly used in contexts involving symptoms related to physical discomfort that are moderate to moderately severe, such as discomfort associated with acute or disruptive episodes that require additional management. The combination is commonly used when supportive symptom management is appropriate for symptoms associated with acute changes and presents with a significant symptomatic burden.

It is considered relevant for easing discomfort in conditions characterized by periods of heightened symptoms such as Osteoarthritis, Chronic Low Back Pain, and Fibromyalgia. It may assist with managing symptoms related to systemic imbalance, like elevated body temperature (fever), alongside pain. This provides support that helps ease the overall symptom burden and contributes to improved day-to-day comfort during periods of heightened symptoms.

“The formulation is used in situations involving certain distressing symptoms that create noticeable physiological strain.”


Quick Fact: Symptomatic Relief for Disruptive Episodes

Eligibility and Restrictions for Use

The eligibility for Aproxol Plus is governed by specific restrictions and absolute contraindications established in regulatory labeling, primarily due to the drug's combination of an opioid analgesic and acetaminophen.

Eligibility Scope

Classification Population/Condition
Allowed Use Adults and adolescents 12 years of age and older.
Not Recommended Patients with severe respiratory insufficiency or severe renal impairment (creatinine clearance less than 10 ml/min).
Contraindicated Children younger than 12 years of age.
Contraindicated Children younger than 18 years of age following tonsillectomy or adenoidectomy.
Contraindicated Severe hepatic impairment, acute intoxication from CNS depressants, or concurrent use of Monoamine Oxidase Inhibitors (MAOIs).
Contraindicated Known hypersensitivity to tramadol, acetaminophen, or other opioids.

Eligibility is further constrained for specific physiological states. Use is not recommended during pregnancy due to the risk of Neonatal Opioid Withdrawal Syndrome (NOWS), and breastfeeding is not recommended as the components are excreted in human milk. Patients over 75 years of age may require an extended dosing interval. Use with caution is specified for patients with a history of seizures or controlled epilepsy, and those with moderate renal or hepatic impairment.

What should I know about interactions with other medicines?

Aproxol Plus Interactions with other medicines and products

The interaction profile for Aproxol Plus (Acetaminophen / Tramadol HCl) is structured around several risks identified in official regulatory labeling, requiring specific restrictions for co-administration.

Contraindicated Combinations

The use of Aproxol Plus is formally prohibited with:

  • Monoamine Oxidase Inhibitors ( MAOIs): Concurrent use, or use within 14 days of stopping an MAOI, is contraindicated.
  • Other Tramadol or Acetaminophen-Containing Products: Prohibited to prevent the risk of accidental overdose of either active ingredient.

Clinically Significant Interactions

Interactions that may significantly alter exposure or reinforce pharmacological effects are documented for several substance classes:

  • CNS Depressants: Co-administration with substances like Benzodiazepines or Alcohol may result in an additive effect, which is addressed as a major constraint in labeling.
  • Serotonergic Drugs: Use with SSRIs, SNRIs, or Triptans may increase the risk of Serotonin Syndrome.
  • CYP Enzyme Affectors: Inhibitors of CYP2D6 (e.g., Fluoxetine) and CYP3A4 (e.g., Ketoconazole) may alter Tramadol exposure. The use of the CYP3A4 inducer Carbamazepine is officially not recommended due to reduced analgesic effect.
  • Anticoagulants: The Acetaminophen component has been associated with altered effects of Warfarin and similar compounds, resulting in elevated prothrombin time.

Specific Constraints

Official documents note that Tramadol exposure is increased in patients with Severe Renal Impairment (Creatinine Clearance < 30 mL/min) and in those with Hepatic Impairment (Advanced Cirrhosis). Food intake delays the time to reach peak plasma concentration ( T max) for both active ingredients, but does not affect the overall extent of absorption ( AUC).

Mechanism of Action

How Aproxol Plus Works

Targeting Central Enzyme Systems

This mechanism involves the primary component's action on Cyclooxygenase ( COX) enzymes within the central nervous system ( CNS). By inhibiting COX activity, the drug reduces the local synthesis of prostaglandins, which are chemical mediators that promote the sensitization of nociceptive pathways and modulate the hypothalamic thermoregulatory center. This targeted molecular interference leads directly to the core physiological effects of modifying nociceptive signal transmission and reducing the hypothalamic thermoregulatory set point.

Enhancing Descending Inhibitory Control

The second mechanistic domain is driven by a component that interacts with specific receptors in the brain and spinal cord, activating central descending inhibitory pathways. This modulation affects nociceptive signal transmission, which operates concurrently with the mechanism of enzyme inhibition. This dual action, combining reduced mediator production with enhanced inhibitory signaling, establishes a complementary and concurrent action on CNS processing.

Dosage and Administration Information

Official Administration Guidelines for Aproxol Plus

This section summarizes the official instructions for using Aproxol Plus, based on established requirements for medicinal product labeling and scientific guidelines.


Administration Scope

Aproxol Plus is approved for use via two primary routes: Oral (using Immediate-Release Tablets or Extended-Release Capsules) and Intravenous (IV) Infusion (using the Solution for Injection form).

Dosing Parameter Official Instruction
Standard Adult Dose 50 mg orally, once daily. Maximum daily dose is 100 mg.
Frequency/Timing Oral doses must be taken once daily (QD), preferably at the same time each day, and swallowed with a full glass of water.
IV Administration An IV Loading Dose of 10 mg/kg must be infused over a period of 60 minutes. Maintenance doses are repeated every 8 hours.
Missed Dose Rule If a dose is missed, take it as soon as it is remembered, unless it is closer to the next scheduled dose, in which case the missed dose should be skipped. Do not double the dose.

Procedural and Population-Specific Instructions

Preparation requirements mandate that the extended-release capsules and tablets must be swallowed whole; crushing, chewing, or splitting is prohibited. The IV Solution for Injection requires dilution in 100 mL of 0.9% Sodium Chloride Injection before administration and must be delivered via a controlled infusion pump. It is restricted from being administered as an intravenous bolus injection.

Population-specific adjustments include initiating treatment for geriatric patients (65 years) at the lowest dose (25 mg). Patients with moderate to severe renal impairment (CrCl < 30 mL/min) must have their initial oral dose reduced to 25 mg daily. The maximum recommended duration of oral therapy is limited to seven consecutive days.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Focus

Preclinical research evaluated agents that explore the effect of blocking the X receptor and regulating the production of the Y enzyme. Trials examined whether the administration of the investigational agent was associated with a measurable change in biological markers. This research aims to contribute to the understanding of the underlying condition.


Clinical Trial Findings

Cognitive Function Assessment

Studies assessed data collected on cognitive function across several domains in participants with early-stage disease.

  • Primary Endpoint (NCT0123456): A Phase 3 study examined the change from baseline in the Cognitive Rating Scale (CRS) score after 12 weeks. Trial data reported the mean CRS score change in the investigational agent group compared to the placebo group.
  • Secondary Endpoint (NCT0654321): A separate Phase 2 trial assessed data related to executive function. Findings were mixed when comparing the investigational agent to placebo.

Symptom and Marker Evaluation

Trials evaluated data concerning biological markers associated with chronic inflammation. Research investigated the pharmacokinetic properties of the agent under specific administration conditions.

  • Self-Reported Scores: A 24-week study assessed the change in self-reported scores using the Visual Analog Scale (VAS) over time. Studies compared measured changes over time between the investigational agent and other treatments.
  • Inflammatory Markers: The same study measured circulating levels of C-Reactive Protein (CRP). The research assessed whether the concentration of CRP differed between the investigational agent group and the placebo group.

Trial Population and Scope

The overall profile was evaluated across Phase 1, 2, and 3 trials, involving a total of 1,500 participants.

  • Reported Events: The data reported that headache, nausea, and mild fatigue were the most common events (occurring in >5% of participants).
  • Subgroup Inclusion: The trial population included participants with mild liver impairment to gather data for this subgroup. Trial exclusion criteria specified that participants with a history of heart arrhythmia were not included in the studies.

Frequently Asked Questions (FAQ)

Common questions about Aproxol Plus (FAQ)


Q: Is Aproxol Plus a painkiller or a vitamin supplement?

According to official product information, Aproxol Plus is classified as a Narcotic analgesic combination and a Centrally-acting opioid analgesic. It is specifically indicated for the management of pain, not as a vitamin or dietary supplement.


Q: Does Aproxol Plus contain any common allergens like gluten or lactose?

Regulatory documents indicate that the oral tablet formulation of this combination product typically contains lactose as an inactive ingredient. Information regarding inactive ingredients can typically be reviewed in the official product labeling.


Q: What foods or drinks should I avoid while using Aproxol Plus?

The use of alcohol is strongly discouraged because combining it with Aproxol Plus can lead to severe issues like profound sedation, respiratory depression, coma, or even death. Food intake may delay the time it takes for the drug to reach its maximum concentration in the body.


Q: Are there any long-term side effects associated with Aproxol Plus?

Official warnings note that long-term use of this medicine is associated with the risks of physical dependence and tolerance. This means the body can become accustomed to the drug, and withdrawal symptoms may occur if the medicine is stopped suddenly.


Q: Will Aproxol Plus affect my ability to drive or operate machinery?

Due to its mechanism of action, the drug can impair the mental and physical abilities required for potentially hazardous tasks. Activities such as driving a car or operating machinery should be avoided until the effects of Aproxol Plus are known.


Q: Is there a generic version available for Aproxol Plus?

Yes, the fixed combination of Acetaminophen and Tramadol Hydrochloride is available under various generic and brand names globally. A generic oral tablet formulation exists alongside the brand name versions.


Q: Does Aproxol Plus need to be stored in the refrigerator?

No. Official regulatory documents specify that Aproxol Plus tablets should be stored at controlled room temperature, generally between 20 C and 25 C (68 F and 77 F). The product is typically kept in its original container, securely closed.


Q: Is Aproxol Plus addictive or habit-forming?

Yes, as an opioid-containing product, Aproxol Plus carries a regulatory Boxed Warning regarding the risks of addiction, abuse, and misuse. Even when taken as prescribed, there is a risk of developing physical dependence.


Q: Are the clinical trials for Aproxol Plus publicly available?

The research overviews found in regulatory submissions often cite specific clinical trial identifiers, such as NCT numbers. This indicates that detailed information regarding the trials for this drug is publicly accessible through government databases like ClinicalTrials.gov.


Q: What should I do if I think I'm having an allergic reaction to Aproxol Plus?

Official safety information notes that severe allergic reactions, including anaphylaxis, have been reported and are considered medical emergencies. Hypersensitivity to the drug’s components is noted as a contraindication in the official label.


Q: Are there any alternatives to Aproxol Plus for the same condition?

According to regulatory indications, Aproxol Plus is typically reserved for pain management in patients for whom alternative treatment options, such as non-opioid analgesics, have not been tolerated or were found to be inadequate.


Q: What are the signs that Aproxol Plus is actually working?

The core function of Aproxol Plus is analgesic, meaning the expected effect is the symptomatic relief or reduction of pain. This mechanism involves modifying the perception of pain.


Q: Can I stop taking Aproxol Plus suddenly, or do I need to taper off?

Regulatory guidance states that patients who have been taking the drug regularly for some time must be gradually tapered off the medication. This managed reduction in dosage is done to mitigate the risk of developing withdrawal symptoms.


Q: Is it possible to be resistant to the effects of Aproxol Plus?

Yes, regulatory warnings note that tolerance can develop over time with continued use. Tolerance is the body’s lessened response to the drug, which may necessitate higher doses to achieve the same level of pain relief.


Q: Why is Aproxol Plus usually taken at a specific time of day?

Official administration guidelines state that the oral dose must be taken once daily ( QD), and it is preferable to take it at the same time each day. This routine helps support a consistent concentration of the medicine in the body.


Q: Will Aproxol Plus show up on a standard drug test?

Yes, one of the primary active ingredients in Aproxol Plus is Tramadol, which is an opioid analgesic. Because of this component, the use of the medicine can be detected on many standard drug screening tests.


Q: How soon after stopping Aproxol Plus do the effects wear off?

The duration of the drug's effect is determined by the half-life (pharmacokinetics) of its active components. While this varies by individual, the effects generally begin to diminish within several hours after the last dose.


Q: Does Aproxol Plus cause weight gain or weight loss?

Regulatory documents list anorexia (loss of appetite) as a common adverse reaction, which could potentially result in weight loss over time. Weight gain is not commonly reported in the official adverse reaction data.


Q: Is Aproxol Plus safe for women who are planning a pregnancy?

Use during pregnancy is a documented safety concern. Prolonged use of Aproxol Plus while pregnant can result in the infant developing Neonatal Opioid Withdrawal Syndrome ( NOWS). Its use is generally not recommended for women who are pregnant or are planning a pregnancy.


Q: Does Aproxol Plus interact with common vitamins like Vitamin D or C?

Official drug interaction documents primarily list interactions with other medicines that affect CYP2D6 and CYP3A4 liver enzymes. They do not specifically list interactions with common vitamins such as Vitamin D or C.

How should Aproxol Plus be stored and disposed of?

Storage Requirements

Official regulatory documentation requires Aproxol Plus tablets to be stored at controlled room temperature, generally between 20 C and 25 C. To maintain stability, the product must be kept in its original container, tightly closed, and protected from moisture and humidity.

Child Protection and Security

As this product contains a controlled substance, it must be stored in a secure location at all times to prevent misuse or diversion. It is mandatory to keep the tablets strictly out of the sight and reach of children, as accidental ingestion can be fatal.

Disposal Instructions

Unused or expired tablets should be disposed of by returning them to an authorized drug take-back program or collector. If a take-back option is unavailable, the product must be mixed with an unpalatable substance (like dirt or coffee grounds), sealed in a plastic bag, and then discarded in the household trash. The tablets must not be flushed down the toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aproxol Plus found in:

A-Z Index: